Clinical Trial Update: Inhaled Budesonide for REcurrence Prevention and Adjuvant THerapy in Checkpoint Inhibitor Pneumonitis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial sponsored by AHS Cancer Control Alberta is recruiting to test inhaled budesonide for recurrence prevention and as adjuvant therapy in c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Checkpoint Inhibitor Pneumonitis
• Pneumonitis

Drugs mentioned

• Budesonide (BUDESONIDE)

Snippet

Sponsor: AHS Cancer Control Alberta | Conditions: Pneumonitis, Immune-related Adverse Event | Phase 2 | Status: RECRUITING